Avoro Capital Advisors LLC: MADRIGAL PHARMACEUTICALS INC (MDGL): Quarterly 13F Position History
As of Q1 2026, Avoro Capital Advisors LLC reported 1,818,181 shares of MADRIGAL PHARMACEUTICALS INC (MDGL), worth $951.8M and representing 9.4% of its 13F equity book. Quarter-over-quarter share count change: + 10,681 (+0.6%) . The position first appeared in Q2 2018 and has been disclosed across 32 13F-HR filings in Pactolio's tracked window.
- 1,818,181Shares Held (Latest Filing)
- $951.8MReported Market Value (Latest Filing)
- 9.4%Portfolio Weight (% of 13F Equity Book)
- +10,681Quarter-over-Quarter Share Change
- -$100.8MQuarter-over-Quarter Value Change
- 2,055,555Peak Reported Shares (Historical)
Quarterly 13F-HR Disclosure History Source: SEC 13F-HR filings, 32 quarter s
| Quarter | Shares | QoQ Share Change | Share Change (%) | Market Value | Weight | Implied Price |
|---|---|---|---|---|---|---|
| Q1 2026 | 1,818,181 | +10,681 | +0.6% | $951.8M | 9.4% | $523.5 |
| Q4 2025 | 1,807,500 | 25,500 | -1.4% | $1.1B | 10.3% | $582.3 |
| Q3 2025 | 1,833,000 | 42,000 | -2.2% | $840.7M | 10.9% | $458.7 |
| Q2 2025 | 1,875,000 | 147,222 | -7.3% | $567.5M | 9.9% | $302.6 |
| Q1 2025 | 2,022,222 | 6,778 | -0.3% | $669.8M | 10.5% | $331.2 |
| Q4 2024 | 2,029,000 | 0 | — | $626.1M | 8.9% | $308.6 |
| Q3 2024 | 2,029,000 | 26,555 | -1.3% | $430.6M | 6.3% | $212.2 |
| Q2 2024 | 2,055,555 | +111,111 | +5.7% | $575.9M | 7.7% | $280.2 |
| Q1 2024 | 1,944,444 | +55,556 | +2.9% | $519.2M | 6.1% | $267.0 |
| Q4 2023 | 1,888,888 | +333,888 | +21.5% | $437.1M | 6.0% | $231.4 |
| Q3 2023 | 1,555,000 | +39,849 | +2.6% | $227.1M | 3.5% | $146.0 |
| Q2 2023 | 1,515,151 | 151,515 | -9.1% | $350.0M | 4.7% | $231.0 |
| Q1 2023 | 1,666,666 | +6,666 | +0.4% | $403.8M | 6.0% | $242.3 |
| Q4 2022 | 1,660,000 | +125,000 | +8.1% | $481.8M | 7.2% | $290.3 |
| Q3 2022 | 1,535,000 | 0 | — | $99.8M | 1.8% | $65.0 |
| Q2 2022 | 1,535,000 | +110,000 | +7.7% | $109.9M | 2.2% | $71.6 |
| Q1 2022 | 1,425,000 | 0 | — | $139.8M | 2.6% | $98.1 |
| Q4 2021 | 1,425,000 | 0 | — | $120.8M | 2.1% | $84.7 |
| Q3 2021 | 1,425,000 | 0 | — | $113.7M | 1.8% | $79.8 |
| Q2 2021 | 1,425,000 | 0 | — | $138.8M | 2.4% | $97.4 |
| Q1 2021 | 1,425,000 | +200,000 | +16.3% | $166.7M | 2.9% | $117.0 |
| Q4 2020 | 1,225,000 | +335,000 | +37.6% | $136.2M | 2.3% | $111.2 |
| Q3 2020 | 890,000 | +540,000 | +154.3% | $105.7M | 1.5% | $118.7 |
| Q2 2020 | 350,000 | +1,000 | +0.3% | $39.6M | 0.8% | $113.3 |
| Q1 2020 | 349,000 | 0 | — | $23.3M | 0.8% | $66.8 |
| Q4 2019 | 349,000 | 11,000 | -3.1% | $31.8M | 0.9% | $91.1 |
| Q3 2019 | 360,000 | 0 | — | $31.0M | 1.3% | $86.2 |
| Q2 2019 | 360,000 | +50,000 | +16.1% | $37.7M | 1.3% | $104.8 |
| Q1 2019 | 310,000 | +85,000 | +37.8% | $38.8M | 1.7% | $125.3 |
| Q4 2018 | 225,000 | 238,000 | -51.4% | $25.4M | 1.5% | $112.7 |
| Q3 2018 | 463,000 | 26,536 | -5.4% | $99.1M | 4.6% | $214.1 |
| Q2 2018 | 489,536 | — | — | $136.9M | 5.3% | $279.7 |
Methodology & FAQ
How This Position History Is Sourced
Each row is one SEC Form 13F-HR filing disclosing this position. Share count, market value, and reported quarter are taken verbatim from the filing; portfolio weight is recomputed against the same filing's total reported equity book. Implied price-per-share is market value divided by shares — a quarter-end mark, not the manager's cost basis. See the full methodology document for the normalization rules.
When did Avoro Capital Advisors LLC first disclose a MDGL position in 13F-HR filings?
Avoro Capital Advisors LLC first reported MADRIGAL PHARMACEUTICALS INC (MDGL) on its 13F-HR filing for the period ending 2018-06-30 (Q2 2018). The position has appeared on 32 reported quarters within Pactolio's tracked window.
What was Avoro Capital Advisors LLC's most recent quarter-over-quarter share-count change in MDGL?
Between Q4 2025 and Q1 2026, Avoro Capital Advisors LLC added 10,681 shares of MDGL (+0.6%), bringing the total reported position to 1,818,181 shares at a market value of $951.8M.
Does the implied price-per-share represent Avoro Capital Advisors LLC's cost basis in MDGL?
No. The implied price-per-share column is the 13F-HR reported market value divided by reported share count on the filing date (end of quarter). It is a quarter-end mark, not a cost basis or transaction price. Use it as a sanity check on the value column, not as an indicator of the manager's entry or exit price.